504125594 12/06/2016

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4172264

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
JEFFREY A. BACHA	11/09/2016
DENNIS M. BROWN	11/09/2016
SANDRA DUNN	12/01/2016
ANNE STEINO	11/04/2016

RECEIVING PARTY DATA

Name:	DELMAR PHARMACEUTICALS, INC.	
Street Address:	720 - 999 WEST BROADWAY	
City:	VANCOUVER	
State/Country:	CANADA	
Postal Code:	V5Z 1K5	

PROPERTY NUMBERS Total: 1

Property Type	Number	
Application Number:	14245738	

CORRESPONDENCE DATA

Fax Number: (703)519-9958

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 7035199951

Email: docket@dcpatent.com

DITTHAVONG & STEINER, P.C. **Correspondent Name:**

Address Line 1: 44 CANAL CENTER PLAZA SUITE 322

Address Line 4: ALEXANDRIA, VIRGINIA 22314

ATTORNEY DOCKET NUMBER:	P6679US01	
NAME OF SUBMITTER:	MICHAEL B. FARBER	
SIGNATURE:	/Michael B. Farber/	
DATE SIGNED:	12/06/2016	

Total Attachments: 8

source=P6679US01_CombinedDecandAssign_filed#page1.tif source=P6679US01 CombinedDecandAssign filed#page2.tif source=P6679US01 CombinedDecandAssign filed#page3.tif

source=P6679US01_CombinedDecandAssign_filed#page4.tif
source=P6679US01_CombinedDecandAssign_filed#page5.tif
source=P6679US01_CombinedDecandAssign_filed#page6.tif
source=P6679US01_CombinedDecandAssign_filed#page7.tif
source=P6679US01_CombinedDecandAssign_filed#page8.tif

44 CANAL CENTER PLAZA, SUITE 322 ALEXANDRIA, VIRGINIA 22314 USA +1-703-519-9951 +1-703-519-9958 FACSIMILE

Attorney Docket No.: P6679US01

Patent

COMBINED DECLARATION AND ASSIGNMENT FOR PATENT APPLICATION

Title of Invention: USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT GLIOBLASTOMA MULTIFORME

As the below named inventor, I hereby declare that this declaration is directed to:

☐ The attached application, or ☐ United States application or PCT international application filed on April 4, 2014 and assigned Serial No. 14/245,738

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment made on (if applicable).

I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

In consideration of good and valuable consideration, the receipt of which is hereby acknowledged, I the undersigned hereby sell, assign, and transfer to DelMar Pharmaceuticals, Inc., a corporation of Canada, having a principal place of business at DelMar Pharmaceuticals, Inc., 720 – 999 West Broadway, Vancouver, British Columbia, V5Z 1K5 ("Assignee"), and its successors, assigns, and legal representatives, the entire right, title, and interest for the United States and all foreign countries, in and to any and all improvements that are disclosed in the above-identified application for the United States patent, which:

and in and to said application and all divisional, continuing, substitute, renewal, reissue, and all other patent applications that have been or shall be filed in the United States and all foreign countries on any of said improvements; and in and to all original and reissued patents that have been or shall be issued in the United States and all foreign countries on said improvements; and in and to all rights of priority resulting from the filing of said United States application;

agree that said Assignee may apply for and receive a patent or patents for said improvements in its own name; and that, when requested, without charge to, but at the expense of, said Assignee, its successors, assigns, and legal representatives, to carry out in good faith the intent and purpose of this Assignment, the undersigned will execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications on any and all said improvements; execute all assignments and powers of attorney; communicate to said Assignee, its successors, assigns, and representatives all facts known to the undersigned relating to said improvements and

44 CANAL CENTER PLAZA, SUITE 322 ALEXANDRIA, VIRGINIA 22314 USA +1-703-519-9958 FACSIMILE

Attorney Docket No.: P6679US01

Patent

the history thereof; and generally assist said Assignee, its successors, assigns, or representatives in securing and maintaining proper patent protection for said improvements and for vesting title to said improvements, and all applications for patents and all patents on said improvements, in said Assignee, its successors, assigns, and legal representatives; and

covenant with said Assignee, its successors, assigns, and legal representatives that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Full Name of First Inventor: Jeffrey A. VACHA

Date

44 CANAL CENTER PLAZA, SUITE 322 ALEXANDRIA, VIRGINIA 22314 USA +1-703-519-9958 FACSIMILE

Attorney Docket No.: P6679US01

Patent

COMBINED DECLARATION AND ASSIGNMENT FOR PATENT APPLICATION

Title of Invention: USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT GLIOBLASTOMA MULTIFORME

As the below named inventor, I hereby declare that this declaration is directed to:

The attached application, or

United States application or PCT international application filed on April 4, 2014 and assigned Serial No. 14/245,738

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment made on (if applicable).

I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

In consideration of good and valuable consideration, the receipt of which is hereby acknowledged, I the undersigned hereby sell, assign, and transfer to DelMar Pharmaceuticals, Inc., a corporation of Canada, having a principal place of business at DelMar Pharmaceuticals, Inc., 720 – 999 West Broadway, Vancouver, British Columbia, V5Z 1K5 ("Assignee"), and its successors, assigns, and legal representatives, the entire right, title, and interest for the United States and all foreign countries, in and to any and all improvements that are disclosed in the above-identified application for the United States patent, which:

and in and to said application and all divisional, continuing, substitute, renewal, reissue, and all other patent applications that have been or shall be filed in the United States and all foreign countries on any of said improvements; and in and to all original and reissued patents that have been or shall be issued in the United States and all foreign countries on said improvements; and in and to all rights of priority resulting from the filing of said United States application;

agree that said Assignee may apply for and receive a patent or patents for said improvements in its own name; and that, when requested, without charge to, but at the expense of, said Assignee, its successors, assigns, and legal representatives, to carry out in good faith the intent and purpose of this Assignment, the undersigned will execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications on any and all said improvements; execute all assignments and powers of attorney; communicate to said Assignee, its successors, assigns, and representatives all facts known to the undersigned relating to said improvements and

44 CANAL CENTER PLAZA, SUITE 322 ALEXANDRIA, VIRGINIA 22314 USA +1-703-519-9958 +1-703-519-9958 FACSIMILE

Attorney Docket No.: P6679US01

Patent

the history thereof; and generally assist said Assignee, its successors, assigns, or representatives in securing and maintaining proper patent protection for said improvements and for vesting title to said improvements, and all applications for patents and all patents on said improvements, in said Assignee, its successors, assigns, and legal representatives; and

covenant with said Assignee, its successors, assigns, and legal representatives that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

Full Name of Second Inventor: Dennis M. BROWN

Inventor's Signature

Date

11-09-16

44 CANAL CENTER PLAZA, SUITE 322 ALEXANDRIA, VIRGINIA 22314 USA +1-703-519-9951 +1-703-519-9958 FACSIMILE

Attorney Docket No.: P6679US01 Patent

COMBINED DECLARATION AND ASSIGNMENT FOR PATENT APPLICATION

Title of Invention: USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT GLIOBLASTOMA MULTIFORME

ERIVATIVES THEREOF TO TREAT GLIOBLASTOMA MULTIFORME
As the below named inventor, I hereby declare that this declaration is directed to:
☐ The attached application, or ☐ United States application or PCT international application filed on April 4, 2014 and assigned Serial No. 14/245,738
The above-identified application was made or authorized to be made by me. I believe that I am the original inventor or an original joint inventor of a claimed

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment made on (if applicable).

invention in the application.

I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

In consideration of good and valuable consideration, the receipt of which is hereby acknowledged, I the undersigned hereby sell, assign, and transfer to DelMar Pharmaceuticals, Inc., a corporation of Canada, having a principal place of business at DelMar Pharmaceuticals, Inc., 720 – 999 West Broadway, Vancouver, British Columbia, V5Z 1K5 ("Assignee"), and its successors, assigns, and legal representatives, the entire right, title, and interest for the United States and all foreign countries, in and to any and all improvements that are disclosed in the above-identified application for the United States patent, which:

and in and to said application and all divisional, continuing, substitute, renewal, reissue, and all other patent applications that have been or shall be filed in the United States and all foreign countries on any of said improvements; and in and to all original and reissued patents that have been or shall be issued in the United States and all foreign countries on said improvements; and in and to all rights of priority resulting from the filing of said United States application;

agree that said Assignee may apply for and receive a patent or patents for said improvements in its own name; and that, when requested, without charge to, but at the expense of, said Assignee, its successors, assigns, and legal representatives, to carry out in good faith the intent and purpose of this Assignment, the undersigned will execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications on any and all said improvements; execute all assignments and powers of attorney; communicate to said Assignee, its successors, assigns, and representatives all facts known to the undersigned relating to said improvements and

44 CANAL CENTER PLAZA, SUITE 322 ALEXANDRIA, VIRGINIA 22314 USA +1-703-519-9951 +1-703-519-9958 FACSIMILE

Attorney Docket No.: P6679US01 Patent

the history thereof; and generally assist said Assignee, its successors, assigns, or representatives in securing and maintaining proper patent protection for said improvements and for vesting title to said improvements, and all applications for patents and all patents on said improvements, in said Assignee, its successors, assigns, and legal representatives; and

covenant with said Assignee, its successors, assigns, and legal representatives that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

	. 0		
	Soulla Dun		
Inventor's Signature	Shallow of Sum	Date	Dec 1, 2016

Full Name of Third Inventor: Sandra DUNN

44 CANAL CENTER PLAZA, SUITE 322 ALEXANDRIA, VIRGINIA 22314 USA +1-703-519-9958 +1-703-519-9958 FACSIMILE

Attorney Docket No.: P6679US01

Patent

FOR PATENT APPLICATION

Title of Invention: USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT GLIOBLASTOMA MULTIFORME

As the below named inventor, I hereby declare that this declaration is directed to:

☐ The attached application, or ☐ United States application or PCT international application filed on April 4, 2014 and assigned Serial No. 14/245,738

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment made on (if applicable).

I acknowledge the duty to disclose all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

In consideration of good and valuable consideration, the receipt of which is hereby acknowledged, I the undersigned hereby sell, assign, and transfer to DelMar Pharmaceuticals, Inc., a corporation of Canada, having a principal place of business at DelMar Pharmaceuticals, Inc., 720 – 999 West Broadway, Vancouver, British Columbia, V5Z 1K5 ("Assignee"), and its successors, assigns, and legal representatives, the entire right, title, and interest for the United States and all foreign countries, in and to any and all improvements that are disclosed in the above-identified application for the United States patent, which:

and in and to said application and all divisional, continuing, substitute, renewal, reissue, and all other patent applications that have been or shall be filed in the United States and all foreign countries on any of said improvements; and in and to all original and reissued patents that have been or shall be issued in the United States and all foreign countries on said improvements; and in and to all rights of priority resulting from the filing of said United States application;

agree that said Assignee may apply for and receive a patent or patents for said improvements in its own name; and that, when requested, without charge to, but at the expense of, said Assignee, its successors, assigns, and legal representatives, to carry out in good faith the intent and purpose of this Assignment, the undersigned will execute all divisional, continuing, substitute, renewal, reissue, and all other patent applications on any and all said improvements; execute all assignments and powers of attorney; communicate to said Assignee, its successors, assigns, and representatives all facts known to the undersigned relating to said improvements and

44 CANAL CENTER PLAZA, SUITE 322 ALEXANDRIA, VIRGINIA 22314 USA +1-703-519-9958 FACSIMILE

Attorney Docket No.: P6679US01

Patent

Nov 4 2016

the history thereof; and generally assist said Assignee, its successors, assigns, or representatives in securing and maintaining proper patent protection for said improvements and for vesting title to said improvements, and all applications for patents and all patents on said improvements, in said Assignee, its successors, assigns, and legal representatives; and

covenant with said Assignee, its successors, assigns, and legal representatives that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by the undersigned, and that full right to convey the same as herein expressed is possessed by the undersigned.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both

Full Name of Forth Inventor: Anne STEINØ

Inventor's Signature

RECORDED: 12/06/2016

Date